1
|
Magarò G, Prati F, Garofalo B, Corso G, Furlotti G, Apicella C, Mangano G, D'Atanasio N, Robinson D, Di Giorgio FP, Ombrato R. Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens. J Med Chem 2019; 62:7445-7472. [PMID: 31276392 DOI: 10.1021/acs.jmedchem.9b00394] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Bacterial resistance is increasing rapidly, requiring urgent identification of new antibacterial drugs that are effective against multidrug-resistant pathogens. Novel bacterial topoisomerase inhibitors (NBTIs) provide a new strategy for investigating the well-validated DNA gyrase and topoisomerase IV targets while preventing cross-resistance issues. On this basis, starting from a virtual screening campaign and subsequent structure-based hit optimization guided by X-ray studies, a novel class of piperazine-like NBTIs with outstanding enzymatic activity against Staphylococcus aureus and Escherichia coli DNA gyrase and topoisomerase IV was identified. Notably, compounds (±)-33, (±)-35, and (±)-36 with potent and balanced multitarget enzymatic profiles exhibited excellent efficacy against selected Gram-positive and Gram-negative pathogens, as well as clinically relevant resistant strains. Overall, the new NBTI chemotype described herein, owing to the broad-spectrum antibacterial activity and favorable in vitro safety profile, might serve as a basis for the development of novel treatments against serious infections.
Collapse
Affiliation(s)
- Gabriele Magarò
- Angelini RR&D (Research, Regulatory & Development) , Angelini S.p.A. , Piazzale della Stazione SNC, S. Palomba-Pomezia , Rome 00071 , Italy
| | - Federica Prati
- Angelini RR&D (Research, Regulatory & Development) , Angelini S.p.A. , Piazzale della Stazione SNC, S. Palomba-Pomezia , Rome 00071 , Italy
| | - Barbara Garofalo
- Angelini RR&D (Research, Regulatory & Development) , Angelini S.p.A. , Piazzale della Stazione SNC, S. Palomba-Pomezia , Rome 00071 , Italy
| | - Gaia Corso
- Angelini RR&D (Research, Regulatory & Development) , Angelini S.p.A. , Piazzale della Stazione SNC, S. Palomba-Pomezia , Rome 00071 , Italy
| | - Guido Furlotti
- Angelini RR&D (Research, Regulatory & Development) , Angelini S.p.A. , Piazzale della Stazione SNC, S. Palomba-Pomezia , Rome 00071 , Italy
| | - Claudia Apicella
- Angelini RR&D (Research, Regulatory & Development) , Angelini S.p.A. , Piazzale della Stazione SNC, S. Palomba-Pomezia , Rome 00071 , Italy
| | - Giorgina Mangano
- Angelini RR&D (Research, Regulatory & Development) , Angelini S.p.A. , Piazzale della Stazione SNC, S. Palomba-Pomezia , Rome 00071 , Italy
| | - Noemi D'Atanasio
- Angelini RR&D (Research, Regulatory & Development) , Angelini S.p.A. , Piazzale della Stazione SNC, S. Palomba-Pomezia , Rome 00071 , Italy
| | - Daniel Robinson
- Schrodinger , 120 West 45th Street , New York , New York 10036 , United States
| | - Francesco Paolo Di Giorgio
- Angelini RR&D (Research, Regulatory & Development) , Angelini S.p.A. , Piazzale della Stazione SNC, S. Palomba-Pomezia , Rome 00071 , Italy
| | - Rosella Ombrato
- Angelini RR&D (Research, Regulatory & Development) , Angelini S.p.A. , Piazzale della Stazione SNC, S. Palomba-Pomezia , Rome 00071 , Italy
| |
Collapse
|
2
|
Furlotti G, Alisi MA, Cazzolla N, Ceccacci F, Garrone B, Gasperi T, La Bella A, Leonelli F, Loreto MA, Magarò G, Mangano G, Bettolo RM, Masini E, Miceli M, Migneco LM, Vitiello M. Targeting Serotonin 2A and Adrenergic α 1 Receptors for Ocular Antihypertensive Agents: Discovery of 3,4-Dihydropyrazino[1,2-b]indazol-1(2H)-one Derivatives. ChemMedChem 2018; 13:1597-1607. [PMID: 29873449 DOI: 10.1002/cmdc.201800199] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 05/18/2018] [Indexed: 01/29/2023]
Abstract
Glaucoma affects millions of people worldwide and causes optic nerve damage and blindness. The elevation of the intraocular pressure (IOP) is the main risk factor associated with this pathology, and decreasing IOP is the key therapeutic target of current pharmacological treatments. As potential ocular hypotensive agents, we studied compounds that act on two receptors (serotonin 2A and adrenergic α1 ) linked to the regulation of aqueous humour dynamics. Herein we describe the design, synthesis, and pharmacological profiling of a series of novel bicyclic and tricyclic N2-alkyl-indazole-amide derivatives. This study identified a 3,4-dihydropyrazino[1,2-b]indazol-1(2H)-one derivative with potent serotonin 2A receptor antagonism, >100-fold selectivity over other serotonin subtype receptors, and high affinity for the α1 receptor. Moreover, upon local administration, this compound showed superior ocular hypotensive action in vivo relative to the clinically used reference compound timolol.
Collapse
Affiliation(s)
- Guido Furlotti
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Maria Alessandra Alisi
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Nicola Cazzolla
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Francesca Ceccacci
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy.,Current affiliation: Istituto di Metodologie Chimiche-CNR, Unità Organizzativa di Supporto, Sede di Roma, Università degli Studi di Roma "La Sapienza", P. le Aldo Moro 5, 00185, Rome, Italy)
| | - Beatrice Garrone
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Tecla Gasperi
- Department of Science, Section of Nanoscience and Nanotechnology, University of Roma Tre, via della Vasca Navale 79, 00146, Rome, Italy
| | - Angela La Bella
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy
| | - Francesca Leonelli
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy.,Dipartimento di Biologia Ambientale, University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy
| | - Maria Antonietta Loreto
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy
| | - Gabriele Magarò
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Giorgina Mangano
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Rinaldo Marini Bettolo
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy
| | - Emanuela Masini
- Departments of NEUROFARBA, Section of Pharmacology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy
| | - Martina Miceli
- Department of Science, Section of Nanoscience and Nanotechnology, University of Roma Tre, via della Vasca Navale 79, 00146, Rome, Italy
| | - Luisa Maria Migneco
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy
| | - Marco Vitiello
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| |
Collapse
|
3
|
Furlotti G, Alisi MA, Cazzolla N, Dragone P, Durando L, Magarò G, Mancini F, Mangano G, Ombrato R, Vitiello M, Armirotti A, Capurro V, Lanfranco M, Ottonello G, Summa M, Reggiani A. Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders. J Med Chem 2015; 58:8920-37. [PMID: 26486317 DOI: 10.1021/acs.jmedchem.5b01208] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Novel treatments for bipolar disorder with improved efficacy and broader spectrum of activity are urgently needed. Glycogen synthase kinase 3β (GSK-3β) has been suggested to be a key player in the pathophysiology of bipolar disorder. A series of novel GSK-3β inhibitors having the common N-[(1-alkylpiperidin-4-yl)methyl]-1H-indazole-3-carboxamide scaffold were prepared taking advantage of an X-ray cocrystal structure of compound 5 with GSK-3β. We probed different substitutions at the indazole 5-position and at the piperidine-nitrogen to obtain potent ATP-competitive GSK-3β inhibitors with good cell activity. Among the compounds assessed in the in vivo PK experiments, 14i showed, after i.p. dosing, encouraging plasma PK profile and brain exposure, as well as efficacy in a mouse model of mania. Compound 14i was selected for further in vitro/in vivo pharmacological evaluation, in order to elucidate the use of ATP-competitive GSK-3β inhibitors as new tools in the development of new treatments for mood disorders.
Collapse
Affiliation(s)
- Guido Furlotti
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Maria Alessandra Alisi
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Nicola Cazzolla
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Patrizia Dragone
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Lucia Durando
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Gabriele Magarò
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Francesca Mancini
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Giorgina Mangano
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Rosella Ombrato
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Marco Vitiello
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Andrea Armirotti
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| | - Valeria Capurro
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| | - Massimiliano Lanfranco
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| | - Giuliana Ottonello
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| | - Maria Summa
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| | - Angelo Reggiani
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| |
Collapse
|
4
|
Furlotti G, Alisi MA, Apicella C, Capezzone de Joannon A, Cazzolla N, Costi R, Cuzzucoli Crucitti G, Garrone B, Iacovo A, Magarò G, Mangano G, Miele G, Ombrato R, Pescatori L, Polenzani L, Rosi F, Vitiello M, Di Santo R. Discovery and Pharmacological Profile of New 1H-Indazole-3-carboxamide and 2H-Pyrrolo[3,4-c]quinoline Derivatives as Selective Serotonin 4 Receptor Ligands. J Med Chem 2012; 55:9446-66. [DOI: 10.1021/jm300573d] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | | | | | | | | | - Roberta Costi
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - Giuliana Cuzzucoli Crucitti
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | - Alberto Iacovo
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | | | - Gaetano Miele
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | - Luca Pescatori
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | - Federica Rosi
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | - Roberto Di Santo
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| |
Collapse
|